Lynsight (formerly LS CancerDiag) has developed DiagMMR, a unique predictive diagnostic test to detect Lynch syndrome. We provide easily interpretable and highly accurate results even before cancers develop, enabling preventive and personalized care. Unlike current methods requiring tumour tissue, DiagMMR only needs a very small skin biopsy of healthy tissue to detect LS in patients and in healthy individuals alike. This allows for an early diagnosis, enabling cancer prediction and preventive treatment, while unaffected family members can be relieved from regular follow-up. This gives clinicians a reliable tool to choose the right treatment for their patients, but also to screen healthy relatives even before tumours develop and provide true personalized care for patients and their families. The company was founded as a spin-off from the University of Helsinki in 2013. The validation of DiagMMR has shown exceptional accuracy for the industry, with a specificity of 100% and sensitivity of 89%. Lynsight has patents in 29 countries across the world, including Europe, the US and China. DiagMMR is an in vitro diagnostic medical device (IVD MD) and the company has obtained the ISO 13485 certification in 2022. Currently the company is preparing for the US market entry.